starting over with new trial, page-8

Erb says his strategy will result in a faster FDA approval for CP1 and CP2 , that is what we all want , with expedited pathway to approval and some procedure changes recommended by surgeons and recovery as an end point will need a new trial anyway , the current plan is too costly and is taking too long we all agree on that , tuck the shares under the bed and see what happens in 6 months or take the loss , no point squealing , mine are going under the bed, Erb wants minimal dilution and maximum price for shareholders , suits me .
We sure need to take a break from all this stress , you never have all eggs in one basket, enjoy the days the best way you can.